Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYN023 with Rabies Vaccines in Healthy Adults
NCT02956746Phase 2Completed
- Sponsor
- Xingmeng Biopharmaceutical
- Start
- Aug 2016
- Primary completion
- Dec 2017
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of zamerovimab + mazorelvimab in rabies, sponsored by Xingmeng Biopharmaceutical. Started Aug 2016; status: completed.
02
Drugs
zamerovimab + mazorelvimab
03
Conditions
rabies
Beyond the preview
Go deeper on NCT02956746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02956746.